Kirk Druey, M.D.

Kirk Druey, M.D.

Credit: NIAID
Chief, Lung and Vascular Inflammation Section

Major Areas of Research

  • The Systemic Capillary Leak Syndrome (Clarkson disease)
  • Fungal-associated asthma
  • Signal mechanisms of G protein-coupled receptors

Program Description

The LVIS conducts broad and in-depth translational research that focuses on fundamental processes underlying allergic inflammation. Our research program includes studies aimed at mechanistic dissection of fungal associated-asthma and exploration of the pathogenesis of the rare vascular disorder resembling systemic anaphylaxis, a condition known as systemic capillary leak syndrome (SCLS, Clarkson disease). SCLS is a life-threatening disorder of unknown etiology in which patients experience spontaneous and recurrent episodes of hypovolemic shock and edema in the absence of allergic triggers. In the area of fungal asthma, we have identified a fungal protease allergen (Alp1) that is deposited in the airways of patients with severe asthma, and we have elucidated detailed mechanisms by which Alp1 promotes airway smooth muscle contraction and bronchoconstriction. Finally, ongoing studies in the LVIS include G protein-coupled receptor (GPCR)-dependent mechanisms of allergic inflammation, more specifically on the role of Regulators of G protein Signaling (RGS) proteins in lung and inflammatory cells.


Dr. Druey obtained his M.D. from Rush Medical College in Chicago, Illinois. In 1992, following a residency in internal medicine at The New York Hospital/Cornell Medical Cent​er, Dr. Druey became a postdoctoral fellow in the NIAID Laboratory of Immunoregulation. He joined the Laboratory of Allergic Diseases in 1997 to become chief of the Molecular Signal Transduction Section. In 2020, the section was renamed the Lung and Vascular Inflammation Section.

Research Group

Zhihui (Sherry) Xie, Ph.D., Staff Scientist
Eunice C. Chan, Ph.D., Biologist

Selected Publications

Cheung PC, Eisch AR, Maleque N, Polly DM, Auld SC, Druey KM. Fatal Exacerbations of Systemic Capillary Leak Syndrome Complicating Coronavirus Disease. Emerg Infect Dis. 2021 Oct;27(10):2529-2534. doi: 10.3201/eid2710.211155.

Chinn IK, Xie Z, Chan EC, Nagata BM, Koval A, Chen WS, Zhang F, Ganesan S, Hong DN, Suzuki M, Nardone G, Moore IN, Katanaev VL, Balazs AE, Liu C, Lupski JR, Orange JS, Druey KM. Short stature and combined immunodeficiency associated with mutations in RGS10. Sci Signal. 2021 Jul 27;14(693):eabc1940. doi: 10.1126/scisignal.abc1940.

Matheny M, Maleque N, Channell N, Eisch AR, Auld SC, Banerji A, Druey KM. Severe Exacerbations of Systemic Capillary Leak Syndrome After COVID-19 Vaccination: A Case Series. Ann Intern Med. 2021 Jun 15:L21-0250. doi: 10.7326/L21-0250

Wong GS, Redes JL, Balenga N, McCullough M, Fuentes N, Gokhale A, Koziol-White C, Jude JA, Madigan LA, Chan EC, Jester WH, Biardel S, Flamand N, Panettieri RA Jr, Druey KM. RGS4 promotes allergen- and aspirin-associated airway hyperresponsiveness by inhibiting PGE2 biosynthesis.  J Allergy Clin Immunol 2020 Mar 19;S0091-6749(20)30372-9.

Raza A, Xie Z, Chan EC, Chen WS, Scott LM, Eisch AR, Krementsov DN, Rosenberg HF, Parikh SM, Blankenhorn EP, Teuscher C, Druey KM. A natural mouse model reveals genetic determinants of Systemic Capillary Leak Syndrome (Clarkson disease). Commun Biol. 2019 Oct 31;2:398. 

Redes JL, Basu T, Ram-Mohan S, Ghosh CC, Chan EC, Sek AC, Zhao M, Krishnan R, Rosenberg HF, Druey KM. Aspergillus fumigatus-Secreted Alkaline Protease 1 Mediates Airways Hyperresponsiveness in Severe Asthma. Immunohorizons 2019 Aug 6;3(8):368-377.. 

Visit PubMed for a complete publication listing.

Clinical Trials

Content last reviewed on